阅读说明：本技术 一种改善骨密度、延缓骨及关节老化的配方 (Formula for improving bone mineral density and delaying bone and joint aging ) 是由 王洪昌 于 2021-07-07 设计创作，主要内容包括：本发明公开了一种改善骨密度、延缓骨及关节老化的配方,本配方设计合理,本配方包括乳矿物盐、壳寡糖、牦牛骨胶原蛋白肽、针叶樱桃粉、白芷提取物、乌梢蛇提取物、纳豆、透明质酸钠,本配方通过各组分的合理配伍,可有效促进钙的吸收,抑制钙的流失速度,实现增加骨密度的功能,对治疗骨关节疾病具有良好的效果,同时可对老年骨关节退变和骨质疏松有很好的修复作用。(The invention discloses a formula for improving bone mineral density and delaying bone and joint aging, which is reasonable in design and comprises milk mineral salt, chitosan oligosaccharide, yak bone collagen peptide, acerola powder, an angelica dahurica extract, a zaocys dhumnade extract, natto and sodium hyaluronate.)

1. The formula for improving bone mineral density and delaying bone and joint aging is characterized by comprising the following components in parts by weight: 30-36 parts of milk mineral salt, 20-26 parts of chitosan oligosaccharide, 13-18 parts of yak bone collagen peptide, 3-7 parts of acerola powder, 1-5 parts of angelica dahurica extract, 1-5 parts of zaocys dhumnade extract, 1-2 parts of natto and 0.1-0.3 part of sodium hyaluronate.

2. The formula for improving bone density and delaying bone and joint aging according to claim 1, which is characterized by comprising the following components in parts by weight: 30 parts of milk mineral salt, 20 parts of chitosan oligosaccharide, 13 parts of yak bone collagen peptide, 3 parts of acerola cherry powder, 1 part of angelica dahurica extract, 1 part of zaocys dhumnade extract, 1 part of natto and 0.1 part of sodium hyaluronate.

3. The formula for improving bone density and delaying bone and joint aging according to claim 1, which is characterized by comprising the following components in parts by weight: 33.3 parts of milk mineral salt, 23.3 parts of chitosan oligosaccharide, 15 parts of yak bone collagen peptide, 5 parts of acerola cherry powder, 2.67 parts of angelica dahurica extract, 2.67 parts of zaocys dhumnade extract, 1.67 parts of natto and 0.267 part of sodium hyaluronate.

4. The formula for improving bone density and delaying bone and joint aging according to claim 1, which is characterized by comprising the following components in parts by weight: 36 parts of milk mineral salt, 26 parts of chitosan oligosaccharide, 18 parts of yak bone collagen peptide, 7 parts of acerola cherry powder, 5 parts of angelica dahurica extract, 5 parts of zaocys dhumnade extract, 2 parts of natto and 0.3 part of sodium hyaluronate.

5. The formulation of claim 1, wherein the formulation is effective for improving bone density and retarding bone and joint aging, and further comprises: the yak bone collagen peptide is prepared by soaking yak bones, washing, decocting, filtering to obtain collagen, and degrading by protease.

6. The formulation of claim 1, wherein the formulation is effective for improving bone density and retarding bone and joint aging, and further comprises: the components are weighed according to the amount, are fully and uniformly mixed, and can be prepared into any one of tablets, capsules, granules, pills, oral liquid preparations, powder or granules according to a conventional preparation method.

Technical Field

The invention relates to a formula, in particular to a formula for improving bone mineral density and delaying bone and joint aging.

Background

Modern medical research has demonstrated that the most robust bone period is 20-40 years old, i.e. the period in which the bone reaches the highest bone mass and the best quality, whether the bone is in the best condition, whether it is healthy, whether it is a male or female, and the like, depending on genetic and environmental factors. Once the age of 40 years is reached, the rate of bone loss exceeds the rate of formation, bone mass begins to decline, bone becomes progressively brittle, and the likelihood of osteoporosis increases with age.

With the increase of the population of the elderly in China, the incidence rate of osteoporosis is on an increasing trend. Degenerative osteoporosis is a physiological osteoporotic condition that occurs with age. Degenerative osteoporosis is manifested as: decreased bone mass, deterioration of bone microstructure, increased bone fragility and susceptibility to fracture. Degenerative osteoporosis is the fundamental rule of skeletal development, growth, aging, and causes many of the diseases, among which calcium deficiency is a recognized factor. The age is a main factor influencing the bone mineral content, and as the age continuously increases, the bone mineral components and bone matrix of a human body are reduced in equal proportion, the bone is thinned, the number of trabeculae is reduced, the possibility of suffering from osteoporosis is increased, meanwhile, the number of collagen is reduced or the quality of the collagen is reduced, and the osteoporosis can be caused by insufficient or excessive calcium intake or loss.

Disclosure of Invention

The technical problem to be solved by the invention is to overcome the defects of the technology and provide a formula for improving bone mineral density and delaying bone and joint aging.

In order to solve the technical problems, the technical scheme provided by the invention is a formula for improving bone mineral density and delaying bone and joint aging, which comprises the following components in parts by weight: 30-36 parts of milk mineral salt, 20-26 parts of chitosan oligosaccharide, 13-18 parts of yak bone collagen peptide, 3-7 parts of acerola powder, 1-5 parts of angelica dahurica extract, 1-5 parts of zaocys dhumnade extract, 1-2 parts of natto and 0.1-0.3 part of sodium hyaluronate.

Preferably, the composition comprises the following components in parts by weight: 30 parts of milk mineral salt, 20 parts of chitosan oligosaccharide, 13 parts of yak bone collagen peptide, 3 parts of acerola cherry powder, 1 part of angelica dahurica extract, 1 part of zaocys dhumnade extract, 1 part of natto and 0.1 part of sodium hyaluronate.

Preferably, the composition comprises the following components in parts by weight: 33.3 parts of milk mineral salt, 23.3 parts of chitosan oligosaccharide, 15 parts of yak bone collagen peptide, 5 parts of acerola cherry powder, 2.67 parts of angelica dahurica extract, 2.67 parts of zaocys dhumnade extract, 1.67 parts of natto and 0.267 part of sodium hyaluronate.

Preferably, the composition comprises the following components in parts by weight: 36 parts of milk mineral salt, 26 parts of chitosan oligosaccharide, 18 parts of yak bone collagen peptide, 7 parts of acerola cherry powder, 5 parts of angelica dahurica extract, 5 parts of zaocys dhumnade extract, 2 parts of natto and 0.3 part of sodium hyaluronate.

Preferably, the yak bone collagen peptide is prepared by soaking yak bones, washing, decocting, filtering to obtain collagen, and degrading by protease.

Preferably, the components are weighed according to the amount, fully and uniformly mixed, and can be prepared into any one of tablets, capsules, granules, pills, oral liquid preparations, powder or granules according to a conventional preparation method.

Compared with the prior art, the invention has the advantages that: the formula is reasonable in design and comprises milk mineral salt, chitosan oligosaccharide, yak bone collagen peptide, acerola cherry powder, an angelica dahurica extract, a zaocys dhumnade extract, natto and sodium hyaluronate.

Detailed Description

The following examples are provided to further illustrate the formulation of the present invention for improving bone density and retarding bone and joint aging.

Example 1

A formula for improving bone mineral density and delaying bone and joint aging comprises the following components in parts by weight: 30 parts of milk mineral salt, 20 parts of chitosan oligosaccharide, 13 parts of yak bone collagen peptide, 3 parts of acerola cherry powder, 1 part of angelica dahurica extract, 1 part of zaocys dhumnade extract, 1 part of natto and 0.1 part of sodium hyaluronate, wherein the components are weighed according to the amount, fully and uniformly mixed, and can be prepared into any one of tablets, capsules, granules, pills, oral liquid preparations, powder or granules according to a conventional preparation method.

Example 2

A formula for improving bone mineral density and delaying bone and joint aging comprises the following components in parts by weight: 33.3 parts of milk mineral salt, 23.3 parts of chitosan oligosaccharide, 15 parts of yak bone collagen peptide, 5 parts of acerola cherry powder, 2.67 parts of angelica dahurica extract, 2.67 parts of zaocys dhumnade extract, 1.67 parts of natto and 0.267 part of sodium hyaluronate, wherein the components are weighed according to the amount, fully and uniformly mixed and can be prepared into any one of tablets, capsules, granules, pills, oral liquid preparations, powders or granules according to a conventional preparation method.

Example 3

A formula for improving bone mineral density and delaying bone and joint aging comprises the following components in parts by weight: 36 parts of milk mineral salt, 26 parts of chitosan oligosaccharide, 18 parts of yak bone collagen peptide, 7 parts of acerola cherry powder, 5 parts of angelica dahurica extract, 5 parts of zaocys dhumnade extract, 2 parts of natto and 0.3 part of sodium hyaluronate, wherein the components are weighed according to the amount, fully and uniformly mixed, and can be prepared into any one of tablets, capsules, granules, pills, oral liquid preparations, powder or granules according to a conventional preparation method.

Example 4 study of the function of the present invention to increase strand density

First, preparation of experiment

1) Selecting 30 experimental white rats with 18 males and females respectively, 25 days old and 50g of body weight, dividing the experimental white rats into three groups according to a random sampling principle, wherein each group comprises 12 males and females respectively, each group comprises 6 females and males respectively, determining the experimental groups as an experimental group 1, an experimental group 2 and a control group according to a random method, and the period of the whole experiment is 60 days.

2) Experimental equipment: DPX-L dual-energy X-ray bone densitometer, Ri Li 7600 type full-automatic biochemical analyzer.

3) Materials for experiments: vitamin A acid, daily feed, calcium carbonate medicine and the finished product of the invention.

The daily feed is a daily feeding feed for white rats;

the finished product of the invention is a composition prepared by adopting the formula of the embodiment 2;

the calcium carbonate medicament is a calcium carbonate product sold on the market.

Second, Experimental methods

1) Experiment for osteoporosis

The rats of experiment group 1, experiment group 2 and control group were administered tretinoin in a dose of 50mg/kg standard once a day for two consecutive weeks.

2) Calcium supplement effect verification experiment

After two weeks, the white rats of the experimental group 1, the experimental group 2 and the control group were fed with daily feed, and the feeding standard was 4g/100g of body weight, three times a day, with 8 hours intervals;

in addition, the finished product of the invention is used for supplementary feeding to 2 rats in the experimental group, and the practical calcium carbonate medicament is used for supplementary feeding to the rats in the control group, wherein the supplementary feeding amount is 3mg/100g of body weight;

on the 15 th, 36 th and 59 th days after the start of the experiment, the blood calcium values of the rats in each group were measured, and the blood calcium values of the rats in each group were obtained using a Hitachi 7600 type full-automatic biochemical analyzer.

After the experiment, all experimental animals were sacrificed and the entire left femur was scanned using a DXP-L dual-energy X-ray bone densitometer, and the average bone density of the bone was used to represent the bone density of the bone.

Third, experimental results

1) Blood calcium value results

The blood calcium values of the rats of the experimental group 1, the experimental group 2 and the control group were measured at 15 days, 36 days and 59 days after the start of the experiment, and the tables were plotted as follows:

according to the table, on the 15 th day after the experiment is started, after tretinoin is infused, the blood calcium levels of the three groups of white rats are very close and have no obvious difference; on day 36, the blood calcium levels of the rats in the three groups are improved, but the blood calcium level of the rats in the level 2 control group of the experimental group tends to be higher than that of the rats in the experimental group 1; on day 59, the blood calcium level of the white rat in the experimental group 2 was higher than that in the control group and the experimental group 1.

2) Bone Density measurement results

Based on the experimental process-related analysis data, the following statistics were made and the following tables were drawn:

group of	Number of experimental animals	Density of right femur (g/cm)2)
			Experimental group 1	12	0.1561±0.003
Experimental group 2	12	0.2011±0.051
			Control group	12	0.1921±0.063

From the results of bone density measurement shown in the above table, the data of bone density in rats of the experimental group 2 were the best.

3) Toxicity test

When the white rats in the experimental group 2 are subjected to the autopsy, no obvious abnormality is found in each main organ, so the finished product described in the example 2 has no toxic or side effect.

Similarly, similar conclusions can be obtained by respectively carrying out the experiments by using the formulas of the embodiment 1 and the embodiment 3, a finished product prepared by the formula has no toxic or side effect on white rats, the formula comprises milk mineral salt, chitosan oligosaccharide, yak bone collagen peptide, acerola cherry powder, an angelica dahurica extract, a zaocys dhumnade extract, natto and sodium hyaluronate, and the formula can effectively promote the absorption of calcium, inhibit the loss speed of the calcium and realize the function of increasing bone density through reasonable compatibility of the components, has a good effect on treating osteoarticular diseases and has a good repairing effect on senile osteoarticular degeneration and osteoporosis.

The invention and its embodiments have been described above, without this being limitative. In summary, those skilled in the art should appreciate that they can readily use the disclosed conception and specific embodiments as a basis for designing or modifying other structures for carrying out the same purposes of the present invention without departing from the spirit and scope of the invention as defined by the appended claims.